ARHGAP29 and famililal cerebral cavernous malformations: Src activity has been reported to inhibit the Rho/Rock pathway [47], a pathway also inhibited by Pak2/Pak4 [48], Rasip1/Arhgap29 [11], and the cerebral cavernous malformation (CCM) proteins, CCM1 and CCM2 [15, 17].